Nitric oxide-independent vasodilator rescues heme-oxidized soluble guanylate cyclase from proteasomal degradation

Circulation Research

Volumn 105, Issue 1, 2009, Pages 33-41

  Meurer, Sabine ^a   Pioch, Sylke ^b   Pabst, Tatjana ^b   Opitz, Nils ^a,b   Schmidt, Peter M ^a,f   Beckhaus, Tobias ^b   Wagner, Kristina ^b   Matt, Simone ^b   Gegenbauer, Kristina ^a,g   Geschka, Sandra ^c,e   Karas, Michael ^b   Stasch, Johannes Peter ^c,d   Schmidt, Harald H H W ^a   Müller Esterl, Werner ^b  

^a MONASH UNIVERSITY   (Australia)

^b GOETHE UNIVERSITY   (Germany)

^c BAYER PHARMA AG   (Germany)

^d MARTIN LUTHER UNIVERSITY HALLE WITTENBERG   (Germany)

^e UNIVERSITY OF COLOGNE   (Germany)

^f CSIRO   (Australia)

^g UNIVERSITY COLLEGE DUBLIN   (Ireland)

Author keywords

BAY 58 2667; Nitric oxide; Proteasome; Soluble guanylate cyclase; Ubiquitination

Indexed keywords

4 [[4 CARBOXYBUTYL[2 [(4 PHENETHYLBENZYL)OXY]PHENETHYL]AMINO]METHYL]BENZOIC ACID; GUANYLATE CYCLASE; HEAT SHOCK PROTEIN 70; HEME; NITRIC OXIDE; PROTEASOME; VASODILATOR AGENT; CELL RECEPTOR; CYCLIC GMP; SOLUBLE GUANYLYL CYCLASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD VESSEL; CONTROLLED STUDY; DOWN REGULATION; DRUG EFFECT; DRUG MECHANISM; HUMAN; HUMAN CELL; HUMAN TISSUE; ISOLATION PROCEDURE; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; RAT; UBIQUITINATION; VASCULAR DISEASE; VASODILATATION; CELL LINE; METABOLISM; OXIDATION REDUCTION REACTION;

BLOOD VESSELS; CELL LINE; CYCLIC GMP; GUANYLATE CYCLASE; HEME; HUMANS; NITRIC OXIDE; OXIDATION-REDUCTION; PROTEASOME ENDOPEPTIDASE COMPLEX; RECEPTORS, CYTOPLASMIC AND NUCLEAR; UBIQUITINATION; VASODILATOR AGENTS;

EID: 67949105076     PISSN: 00097330     EISSN: 15244571     Source Type: Journal    
DOI: 10.1161/CIRCRESAHA.109.198234     Document Type: Article

References (43)

1. Melichar VO, Behr-Roussel D, Zabel U, Uttenthal LO, Rodrigo J, Rupin A, Verbeuren TJ, Kumar HSA, Schmidt HHHW. Reduced cGMP signaling associated with neointimal proliferation and vascular dysfunction in late-stage atherosclerosis. Proc Natl Acad Sci U S A. 2004;101: 16671-16676.
2. Hare JM. Nitroso-redox balance in the cardiovascular system. N Engl J Med. 2004;351:2112-2114.
3. Harrison DG. Endothelial function and oxidant stress. Clin Cardiol. 1997;20:II-11-II-7.
4. Pryor WA, Squadrito GL. The chemistry of peroxynitrite: a product from the reaction of nitric oxide with superoxide. Am J Physiol. 1995;268: L699-L722.
5. Bauersachs J, Bouloumie A, Mulsch A, Wiemer G, Fleming I, Busse R. Vasodilator dysfunction in aged spontaneously hypertensive rats: changes in NO synthase III and soluble guanylyl cyclase expression, and in superoxide anion production. Cardiovasc Res. 1998;37:772-779.
6. Kloss S, Bouloumie A, Mulsch A. Aging and chronic hypertension decrease expression of rat aortic soluble guanylyl cyclase. Hypertension. 2000;35:43-47.
7. Ruetten H, Zabel U, Linz W, Schmidt HHHW. Downregulation of soluble guanylyl cyclase in young and aging spontaneously hypertensive rats. Circ Res. 1999;85:534-541.
8. Chen L, Daum G, Fischer JW, Hawkins S, Bochaton-Piallat ML, Gabbiani G, Clowes AW. Loss of expression of the beta subunit of soluble guanylyl cyclase prevents nitric oxide-mediated inhibition of DNA synthesis in smooth muscle cells of old rats. Circ Res. 2000;86: 520-525.
9. Friebe A, Mergia E, Dangel O, Lange A, Koesling D. Fatal gastrointestinal obstruction and hypertension in mice lacking nitric oxidesensitive guanylyl cyclase. Proc Natl Acad Sci U S A. 2007;104: 7699-7704.
10. Papapetropoulos A, Zhou Z, Gerassimou C, Yetik G, Venema RC, Roussos C, Sessa WC, Catravas JD. Interaction between the 90-kDa heat shock protein and soluble guanylyl cyclase: physiological significance and mapping of the domains mediating binding. Mol Pharmacol. 2005; 68:1133-1141.
11. Zhou Z, Gross S, Roussos C, Meurer S, Müller-Esterl W, Papapetropoulos A. Structural and functional characterization of the dimerization region of soluble guanylyl cyclase. J Biol Chem. 2004;279:24935-24943.
12. Nedvetsky PI, Meurer S, Opitz N, Nedvetskaya TY, Muller H, Schmidt HH. Heat shock protein 90 regulates stabilization rather than activation of soluble guanylate cyclase. FEBS Lett. 2008;582:327-331.
13. Stasch JP, Schmidt PM, Nedvetsky PI, Nedvetskaya TY, H SA, Meurer S, Deile M, Taye A, Knorr A, Lapp H, Muller H, Turgay Y, Rothkegel C, Tersteegen A, Kemp-Harper B, Müller-Esterl W, Schmidt HHHW. Targeting the heme-oxidized nitric oxide receptor for selective vasodilatation of diseased blood vessels. J Clin Invest. 2006;116:2552-2561.
14. Denninger JW, Marletta MA. Guanylate cyclase and the NO/cGMP signaling pathway. Biochim Biophys Acta. 1999;1411:334-350.
15. Krumenacker JS, Hanafy KA, Murad F. Regulation of nitric oxide and soluble guanylyl cyclase. Brain Res Bull. 2004;62:505-515.
16. Schrammel A, Behrends S, Schmidt K, Koesling D, Mayer B. Characterization of 1H-[1,2,4]oxadiazolo[4,3-a]quinoxalin-1-one as a heme-site inhibitor of nitric oxide-sensitive guanylyl cyclase. Mol Pharmacol. 1996;50:1-5.
17. Zhao Y, Brandish PE, DiValentin M, Schelvis JP, Babcock GT, Marletta MA. Inhibition of soluble guanylate cyclase by ODQ. Biochemistry. 2000;39:10848-10854.
18. Garthwaite J, Southam E, Boulton CL, Nielsen EB, Schmidt K, Mayer B. Potent and selective inhibition of nitric oxide-sensitive guanylyl cyclase by 1H-[1,2,4]oxadiazolo[4,3-a]quinoxalin-1-one. Mol Pharmacol. 1995; 48:184-188.
19. Schmidt PM, Schramm M, Schroder H, Wunder F, Stasch JP. Identification of residues crucially involved in the binding of the heme moiety of soluble guanylate cyclase. J Biol Chem. 2004;279:3025-3032.
20. Stasch JP, Schmidt P, Alonso-Alija C, Apeler H, Dembowsky K, Haerter M, Heil M, Minuth T, Perzborn E, Pleiss U, Schramm M, Schroeder W, Schroder H, Stahl E, Steinke W, Wunder F. NO-and haem-independent activation of soluble guanylyl cyclase: molecular basis and cardiovascular implications of a new pharmacological principle. Br J Pharmacol. 2002; 136:773-783.
21. Nedvetsky PI, Kleinschnitz C, Schmidt HHHW. Regional distribution of protein and activity of the nitric oxide receptor, soluble guanylyl cyclase, in rat brain suggests multiple mechanisms of regulation. Brain Res. 2002;950:148-154.
22. Meurer S, Pioch S, Gross S, Müller-Esterl W. Reactive oxygen species induce tyrosine phosphorylation of and Src kinase recruitment to NO-sensitive guanylyl cyclase. J Biol Chem. 2005;280:33149-33156.
23. Priviero FB, Baracat JS, Teixeira CE, Claudino MA, De Nucci G, Antunes E. Mechanisms underlying relaxation of rabbit aorta by BAY 41-2272, a nitric oxide-independent soluble guanylate cyclase activator. Clin Exp Pharmacol Physiol. 2005;32:728-734.
24. Meurer S, Pioch S, Wagner K, Müller-Esterl W, Gross S. AGAP1, a novel binding partner of nitric oxide-sensitive guanylyl cyclase. J Biol Chem. 2004;279:49346-49354.
25. Olesen SP, Drejer J, Axelsson O, Moldt P, Bang L, Nielsen-Kudsk JE, Busse R, Mulsch A. Characterization of NS 2028 as a specific inhibitor of soluble guanylyl cyclase. Br J Pharmacol. 1998;123:299-309.
26. Schindler U, Strobel H, Schonafinger K, Linz W, Lohn M, Martorana PA, Rutten H, Schindler PW, Busch AE, Sohn M, Topfer A, Pistorius A, Jannek C, Mulsch A. Biochemistry and pharmacology of novel anthranilic acid derivatives activating heme-oxidized soluble guanylyl cyclase. Mol Pharmacol. 2006;69:1260-1268.
27. Balashova N, Chang FJ, Lamothe M, Sun Q, Beuve A. Characterization of a novel type of endogenous activator of soluble guanylyl cyclase. J Biol Chem. 2005;280:2186-2196.
28. Venema RC, Venema VJ, Ju H, Harris MB, Snead C, Jilling T, Dimitropoulou C, Maragoudakis ME, Catravas JD. Novel complexes of guanylate cyclase with heat shock protein 90 and nitric oxide synthase. Am J Physiol Heart Circ Physiol. 2003;285:H669-H678.
29. Ballinger CA, Connell P, Wu Y, Hu Z, Thompson LJ, Yin LY, Patterson C. Identification of CHIP, a novel tetratricopeptide repeat-containing protein that interacts with heat shock proteins and negatively regulates chaperone functions. Mol Cell Biol. 1999;19:4535-4545.
30. Connell P, Ballinger CA, Jiang J, Wu Y, Thompson LJ, Hohfeld J, Patterson C. The co-chaperone CHIP regulates protein triage decisions mediated by heat-shock proteins. Nat Cell Biol. 2001;3:93-96.
31. Murad F. Shattuck Lecture. Nitric oxide and cyclic GMP in cell signaling and drug development. N Engl J Med. 2006;355:2003-2011.
32. Evgenov OV, Pacher P, Schmidt PM, Hasko G, Schmidt HHHW, Stasch JP. NO-independent stimulators and activators of soluble guanylate cyclase: discovery and therapeutic potential. Nat Rev Drug Discov. 2006; 5:755-768.
33. Roy B, Mo E, Vernon J, Garthwaite J. Probing the presence of the ligand-binding haem in cellular nitric oxide receptors. Br J Pharmacol. 2008;153:1495-1504.
34. Nishida T, Terashima M, Fukami K, Yamada Y. PIASy controls ubiquitination-dependent proteasomal degradation of Ets-1. Biochem J. 2007;405:481-488.
35. Wang X, Trotman LC, Koppie T, Alimonti A, Chen Z, Gao Z, Wang J, Erdjument-Bromage H, Tempst P, Cordon-Cardo C, Pandolfi PP, Jiang X. NEDD4-1 is a proto-oncogenic ubiquitin ligase for PTEN. Cell. 2007;128:129-139.
36. Bache KG, Slagsvold T, Stenmark H. Defective downregulation of receptor tyrosine kinases in cancer. EMBO J. 2004;23:2707-2712.
37. Ferguson SS. Evolving concepts in G protein-coupled receptor endocytosis: the role in receptor desensitization and signaling. Pharmacol Rev. 2001;53:1-24.
38. Hoffmann LS, Schmidt PM, Keim Y, Schaefer SS, Schmidt HHHW, Stasch JP. Distinct molecular requirements to activate and stabilize soluble guanylyl cyclase upon haem oxidation-induced degradation. Br J Pharmacol. In press.
39. Ciechanover A. Proteolysis: from the lysosome to ubiquitin and the proteasome. Nat Rev Mol Cell Biol. 2005;6:79-87.
40. Orlowski M, Wilk S. Ubiquitin-independent proteolytic functions of the proteasome. Arch Biochem Biophys. 2003;415:1-5.
41. Asher G, Tsvetkov P, Kahana C, Shaul Y. A mechanism of ubiquitinindependent proteasomal degradation of the tumor suppressors p53 and p73. Genes Dev. 2005;19:316-321.
42. Sharina IG, Jelen F, Bogatenkova EP, Thomas A, Martin E, Murad F. Alpha1 soluble guanylyl cyclase (sGC) splice forms as potential regulators of human sGC activity. J Biol Chem. 2008;283:15104-15113.
43. Xia T, Dimitropoulou C, Zeng J, Antonova GN, Snead C, Venema RC, Fulton D, Qian S, Patterson C, Papapetropoulos A, Catravas JD. Chaperone-dependent E3 ligase CHIP ubiquitinates and mediates proteasomal degradation of soluble guanylyl cyclase. Am J Physiol Heart Circ Physiol. 2007;293:H3080-H3087.